Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Definium Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Definium Therapeutics's regulatory disclosures and financial reporting.
Definium Therapeutics reported positive topline Phase 3 results from its Emerge study of DT120 ODT 100 µg in adults with major depressive disorder. The trial met its primary endpoint, showing an 8.1-point placebo-adjusted improvement in MADRS depression scores at Week 6 (p<0.0001), and maintained a 7.3-point advantage at Week 12 (p<0.0001). A key secondary endpoint, the CGI-S severity scale, also improved rapidly, with a 0.9-point placebo-adjusted benefit by Day 2 (p<0.0001). DT120 ODT was generally well tolerated, with 99% of treatment-emergent adverse events mild to moderate, no serious adverse events, and no suicidality signal, and all participants cleared the monitored dosing session by 8 hours. Response and remission rates at Week 6 favored DT120 ODT, and interim extension data suggest additional open-label doses can deepen and sustain benefit through Week 28.
Definium Therapeutics director Crystal Roger received new equity awards as part of her compensation. She was granted 4,666 restricted stock units, each representing the right to receive one common share, and now holds 24,289 common shares after this award.
Roger was also granted a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with any remaining unvested portion vesting immediately before the company’s next annual meeting if it occurs within a year, subject to her continued service.
Definium Therapeutics director David W. Gryska received equity awards as part of his compensation. He was granted 4,666 restricted stock units, each representing one common share, and now holds 19,900 common shares directly after this grant. The filing also reports a grant of stock options for 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036.
The restricted stock units and options each vest as to 1/12 of the underlying shares on every monthly anniversary of the grant date. If the company’s first annual meeting after the grant occurs before the first anniversary, any remaining unvested RSUs and options will vest immediately before that meeting, subject to his continued service.
Definium Therapeutics director Carol A. Vallone received equity-based compensation consisting of restricted stock units and stock options. She was granted 4,666 RSUs, each representing one common share at no purchase price, bringing her direct holdings to 21,210 common shares.
Vallone also received a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest in 12 equal monthly installments from the grant date, with any remaining unvested portion vesting earlier immediately before the issuer’s next annual meeting if it occurs within the first year, subject to her continued service.
Definium Therapeutics director Andreas Krebs received new equity awards. He was granted 4,666 restricted stock units, each representing one common share, and a stock option covering 19,188 common shares at an exercise price of $24.11 per share. Following the award, he directly holds 19,773 common shares, and the option vests in 12 equal monthly installments, with both the RSUs and option subject to possible acceleration immediately before the next annual meeting if it occurs within one year of grant and he continues in service.
Definium Therapeutics director Roger Adsett reported equity awards consisting of 3,555 common shares in the form of restricted stock units and 14,620 stock options. The options carry an exercise price of $24.11 per share and expire on June 10, 2036.
Both the RSUs and options vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with any remaining unvested portion vesting immediately before the issuer’s next annual meeting if it occurs before the first anniversary, subject to his continued service. Following these grants, Adsett holds 3,555 common shares and 14,620 options directly.
Definium Therapeutics director Suzanne Louise Bruhn received equity compensation on common shares. She was granted 4,666 restricted stock units, each representing one future common share, and a stock option for 19,188 common shares at an exercise price of $24.11 per share.
The RSUs and the stock option each vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with remaining unvested awards vesting immediately before the company’s next annual meeting if it occurs within the first year, subject to her continued service. Following these grants, she directly holds 24,289 common shares.
Definium Therapeutics, Inc. reported results of its 2026 Annual General and Special Meeting of Shareholders. Investors approved an amendment to the 2025 Equity Incentive Plan, adding 5,000,000 common shares available for future equity awards to employees and other eligible participants.
Shareholders also elected seven directors to serve until the 2027 annual meeting and approved the appointment of KPMG LLP as the company’s independent registered public accounting firm. A quorum was achieved, with 78,673,592 common shares present or represented, about 72% of the 109,066,783 shares entitled to vote as of April 15, 2026.
Definium Therapeutics, Inc. filed an 8‑K to share an updated May 2026 corporate presentation detailing its late‑stage psychedelic‑derived CNS pipeline and financial position. Lead candidate DT120 ODT (lysergide tartrate) is in five Phase 3 studies across generalized anxiety disorder (GAD), major depressive disorder (MDD) and post‑traumatic stress disorder.
The company highlights Phase 2b data in GAD showing a 21.9‑point improvement on the HAM‑A at week 12 for the 100 µg dose, with a 7.7‑point advantage over placebo and 48% remission at week 12, alongside a generally favorable tolerability profile. Three Phase 3 readouts for DT120 are anticipated in 2026, and the FDA has granted Breakthrough Therapy Designation.
Second program DT402 (R(‑)‑MDMA) is in a Phase 2a autism spectrum disorder study after a well‑tolerated Phase 1 trial. Definium reports cash, cash equivalents and investments of $373.4 million and access to a credit facility up to $120 million as of March 31, 2026, supporting a cash runway into 2028, with 109.1 million shares outstanding as of April 30, 2026 and first‑quarter 2026 operating expenses of $59.2 million.
Definium Therapeutics, Inc. is the subject of a Schedule 13G/A reporting that Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin beneficially own 3,000,000 common shares, representing 3.01% of the class as of March 31, 2026. The filing states the outstanding share base used for the calculation was 99,698,129 common shares as of February 19, 2026, cited from the issuer's Form 10-K. The filing is a joint statement signed by David Kroin on behalf of the reporting persons and clarifies that Deep Track Capital, LP is the relevant entity for which Kroin may be considered a control person.